BACKGROUND:Metoclopramide is widely used for nausea and vomiting of pregnancy and hyperemesis gravidarum. While it is known to cause depressive symptoms as an adverse drug reaction, it is unclear if pregnancy increases this risk. OBJECTIVE:To assess whether metoclopramide-induced depressive symptoms are more common in pregnant women compared to nonpregnant women. to assess whether metoclopramide-induced depressive symptoms are more common in pregnant women compared to nonpregnant women. METHODS:A disproportionality analysis was performed using the national spontaneous adverse drug reaction reporting system of the Netherlands. All reports of adverse drug reactions associated with metoclopramide concerning women aged 15-50 years were included. Based on Medical Dictionary for Regulatory Activities-coded terms and case narratives, pregnancy status was determined. Cases were defined as reports on depressive symptoms. A case review was performed. Disproportionality in reporting between pregnant and nonpregnant women was evaluated using a reporting odds ratio with 95% confidence interval. For comparison, 2 other antiemetic drugs (ondansetron and meclozine with pyridoxine) were also assessed. RESULTS:Reports of depressive symptoms associated with metoclopramide use were reported more often in pregnant women (21.1%) than in nonpregnant women (3.0%; reporting odds ratio 8.6; 95% confidence interval 3.2-23.2). In pregnancy-related cases, depressive symptoms were reported more often following metoclopramide exposure (21.1%) compared to exposure to other antiemetics (7.3%; reporting odds ratio 3.4; 95% confidence interval 1.2-9.3). In 33.3% of the pregnancy-related cases, suicidality tendency was reported. Depressive symptoms were often accompanied by other mood-related symptoms including anxiety, panic attacks, agitation, and restlessness. CONCLUSIONS:Although a causal relationship cannot be established, metoclopramide exposure during pregnancy was associated with increased reporting of depressive symptoms compared to both nonpregnant women and exposure to other antiemetics during pregnancy. This may be explained by a combination of pregnancy-related factors and the pharmacological mechanism of metoclopramide. Given the frequent co-occurrence of suicidal tendency, awareness of this possible adverse drug reaction is crucial for early recognition and prompt intervention to prevent symptom progression and improve maternal safety.
PurposePrescribing cascades occur when an adverse drug reaction (ADR) of a first medication is treated with a second medication, potentially leading to polypharmacy and harm. While various interventions are recommended to prevent harm, it is unknown which are implemented in daily practice. This study aims to assess the interventions implemented for ADRs of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB).MethodsThis cross-sectional study analysed secondary data from spontaneous ADR reports submitted to the Netherlands Pharmacovigilance Center Lareb. Reports were included if the ADR was suspected to be caused by an ACE inhibitor or ARB and an intervention was documented. The primary outcome was the proportion of ADRs treated with (1) dose reduction, (2) discontinuation of the suspected medication, (3) discontinuation followed by medication to treat the ADR, (4) switching to alternative medication, or (5) addition of marker medication (prescribing cascade). The secondary outcome was the proportion of ADRs resolved at the time of the ADR report.ResultsA total of 902 ADR reports were included. The most frequent intervention was discontinuing the suspected medication, followed by introducing medication to treat the ADR (42.5%), resulting in a large proportion of resolved ADRs (46.5%). However, 11.9% of reports included prescribing cascades, resolving the ADR in only 25.2% of reports.ConclusionUsing real-world pharmacovigilance data, this study offers valuable insights into the treatment of ADRs of ACE inhibitors and ARBs in daily practice. Further research is needed to establish the most effective interventions for specific types of ADRs.
A focus group organised by the Drug Safety Research Unit (DSRU) International Working Group (IWG) on New Developments in Pharmacovigilance discussed current challenges and opportunities in pharmacovigilance (PV), emphasising the need for a multimodal approach in data analysis and accessibility of diverse data sources for drug safety surveillance. Nine participants, selected purposefully for their multisectoral expertise in PV, discussed the value of various data types, including data from clinical trials and real-world data (RWD), each offering distinct strengths and limitations. Key challenges identified included data standardisation, quality variability, technological barriers and ethical concerns, particularly with data derived from social media. Emerging tools such as knowledge graphs were highlighted for their potential to enhance data integration and signal detection, however further research is required. The group also addressed disparities in data access, with particular attention to regulatory restrictions, limited infrastructure in low-resource settings and restricted access to industry-held data. Proposed solutions included fostering greater data transparency, establishing secure data-sharing platforms and forming collaborative consortia to facilitate responsible and ethical data use. Overall, the discussion underscored the need for improved integration, access and methodological rigour to strengthen PV practices and enhance global drug safety monitoring.
The COVID-19 mass vaccination led to a substantial increase in spontaneous reports submitted to pharmacovigilance (PV) databases, potentially introducing masking effects that could conceal safety signals. To examine the masking effect of COVID-19 vaccines on disproportionality analyses and to compare two unmasking interventions in the Dutch (Lareb database) and Spanish (Farmacovigilancia Española, Datos de Reacciones Adversas, FEDRA) national PV databases: removal of all drug–event combinations (DEC) involving a COVID-19 vaccine versus excluding influential outliers DECs only. The masking effect was explored retrospectively on the basis of the number of signals of disproportionate reporting (SDR). DECs involving a COVID-19 vaccine were excluded using crude and outlier techniques, and reporting odds ratios were recalculated. Subsets of important medical events (IME) were analysed in both databases. Both crude and influential outlier removal methods led to reductions in the number of reports, DECs and SDRs. Both in the Lareb database and FEDRA, crude removal excluded 2.1